MedTrace Logo

Burosumab in Children and Adolescents With X-linked Hypophosphatemia

NCT04419363 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2020-06-05

No results posted yet for this study

Summary

In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for \<13- and \>13-years old children affected with X-linked hypophosphatemia.

57 children with XLH were switched from conventional treatment to burosumab. After 12 months we assessed the efficacy and safety of treatment with burosumab on the whole cohort and separately on the cohort of \>13-years old adolescents.

Conditions

Interventions

DRUG

Burosumab Injection

Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab

Sponsors & Collaborators

  • Bicetre Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-18
Primary Completion
2019-03-20
Completion
2022-09-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04419363 on ClinicalTrials.gov